RATIONALE

The treatment of patients with chronic myeloid leukemia (CML) deeply evolved during last years. In particular, the introduction of Tyrosine Kinase inhibitors (TKIs) allowed a chronicization of the disease.

Having reached the goal of survival almost equal to that of a control population without leukemia, the main questions regard the treatment of the small number of patients still resistant to therapy, the choice of firstline TKI according to the patient's profile and his primary hematologic objective, the long-term toxicity problems due to continuous TKI intake, the de-scalation of therapy based on the concept of minimal effective dose in state of the maximum tolerated dose, the need to increase the percentage of patients who can maintain a continuous remission even in the absence of TKI therapy (Treatment Free Remission - TFR), and the quality of life of patients.

The meeting, is also devoted to the improvements of the Ph-negative myeloproliferative disorders (MPN), such as the Polycitemia Vera, the Thrombocytemia and moreover the Myelofibrosis.

The most influential and distinguished Italian and International Hematologists will discuss on the most important open questions and projects regardind the CML and the Ph-neg MPN.

FACULTY

Jane Apperley (London) Simona Bernardi (Brescia) Monica Bocchia (Siena) Massimiliano Bonifacio (Verona) Massimo Breccia (Roma) Fausto Castagnetti (Bologna) Daniela Cilloni (Torino) Mirko Farina (Brescia) Carmen Fava (Torino) Nico Gagelmann (Hamburg) Sara Galimberti (Pisa) Carlo Gambacorti Passerini (Monza) Enrico Gottardi (Torino) Antonella Gozzini (Firenze) Paola Guglielmelli (Firenze) Alessandra Iurlo (Milano) Barbara Izzo (Napoli) Roberto Latagliata (Roma) Thomas Lion (Vienna)

Alessandro Lucchesi (Meldola) Michele Malagola (Brescia) Giovanni Martinelli (Meldola) Donal McLornan (London) Barbara Mora (Milano) Olga Mulas (Cagliari) Francesca Palandri (Bologna) Giuseppe A. Palumbo (Catania) Fabrizio Pane (Napoli) Nicola Polverelli (Pavia) Philippe Rousselot (Le Chesnay) Domenico Russo (Brescia) Giuseppe Saglio (Torino) Susanne Saussele (Mannheim) Simona Soverini (Bologna) Giorgina Specchia (Bari) Mario Tiribelli (Udine) Anna Vedovati (Brescia) Daniela Zizioli (Brescia)

Under the Patronage of

GITMO



Con il Patrocinio di SIE Società Italiana di Ematologia



ORGANIZERS Domenico Russo, Giuseppe Saglio, Nicola Polverelli

SCIENTIFIC COMMITTEE Simona Bernardi, Michele Malagola, Alessandro Leoni

The Conference has been accredited by the Italian Ministry of Health: Event n. 652-405010 Provider n. 652


10 ECM credits for n. 100 participants Physicians, Nurses, Biologists, TSLBs, Pharmacists

Each participant, to obtain ECM credits, must be present at least 90% of the scientific work and complete the online ECM questionnaire with a total of 75% of correctanswers. Attendance will be registered via barcode reader.

ORGANIZING SECRETARIAT

DStudio **N** Progress

StudioProgress Snc Via Cattaneo 51 25121 Brescia (Bs) Tel. +39 (0)30 290326 E-mail info@studioprogress.it Web www.studioprogress.it



(^{III}) Bristol Myers Squibb



D. Russo G. Saglio N. Polverelli

S. Bernardi M. Malaaola A. Leoni

Second International "Michele Baccarani" Conference CML and Ph negative **Myeloproliferative Disorders: Biological - Traslational - Clinical**

Features and Perspectives

Brescia, 22-23 Marzo 2024

Organizers

Scientific Secretariat

FIRST DAY 22 MARZO 2024

14.00-14.15	Presentation of the Meeting Giuseppe Saglio, Domenico Russo, Nicola Polverelli	
14.15-15.45	Session 1 • CML Biology: What's new Chairmen: Giovanni Martinelli, Giorgina Specchia How searching Ph+ LSC (15 Min) Monica Bocchia Genetic instability of Ph+ LSC: primary vs secondary (15 Min) Simona Soverini Added value of next generation over Sanger sequencing to determine outcome after resistance to first line TKI therapy (15 Min) Anna Vedovati	
	How monitoring BCR/ABL1 transcript (15 Min) Simona Bernardi How targeting Ph+ LSC (15 Min) Daniela Cilloni Zebrafish for testing efficacy and safety of TKIs (15 Min) Daniela Zizioli	18.35
15.45-16.15	Coffee break	
16.15-17.15	CML Session 2: Advances in CML treatment in Europe Chairmen: Susanne Saussele, Fabrizio Pane	
	In Italy (20 Min) Fausto Castagnetti In France (20 Min) Philippe Rousselot In Germany (20 Min)	19.30
	Susanne Saussele	

17.15-19.30 CML Session 3: Moving to personalized CML treatment

Chairmen:	Giuseppe	Saglio,	Domenico	Russo

I Part Is the survival reached for all CML patients - Discussants (20 Min) Yes Olga Mulas No

Mario Tiribelli

What are the new objectives for CML pts? - Discussant (20 Min)	11.00-
Cure	
Fausto Castagnetti	
Quality of Life	
Michele Malagola	
TFR for all? - Discussants (20 Min)	
Yes	
Carmen Fava	12.00
No	
Alessandra Iurlo	13.00
Escalation for eradication - Discussants (20 Min)	14.30
Yes	14.50
Massimo Breccia	
No	
Mirko Farina	
ll part	
Different drug and/or different strategies for different patients?	
Clinical case 1 (adult 73yy low risk pt) - Discussant (15 min)	
Massimiliano Bonifacio	
Clinical case 2 (adult 37yy int risk pt) - Discussant (15 min)	
Antonella Gozzini	
Clinical case 3 (adult 56yy high risk pt) - Discussant (15 min)	
Roberto Latagliata	
Discussion	
End of the first day	15.30

SECOND DAY 23 MARZO 2024

09.00-10.30 Session 4 - Driving the future in CML Therapy

10.30-11.00

Chairmen: Susanne Saussele, Giuseppe Saglio
Combinatorial treatment options for highly resistant BCR::ABL1 compound mutations (20 Min) Thomas Lion
Reduction of TKI dosage in maintenance therapy (20 Min) Michele Malagola
What do we have to fear as Long term Toxicity? (20 Min) Carlo Gambacorti Passerini
What is new in ELN guidelines 2024 (20 Min) Jane Apperley
Discussion
Coffee Break

Session 5 - News from Labs -11.45 Chairmen: Giovanni Martinelli, Simona Bernardi New diagnostic and prognostic tools (20 Min) Sara Galimberti How to move from RTq-PCR to dPCR Labnet (25 Min) Enrico Gottardi and Barbara Izzo Discussion D-13.00 Baccarani Lecture • CML: the story's not over yet! Jane Apperley -14.30 Lunch Break -15.30 Session 6 - Myelofibrosis: the route to cure Moderator: Donal McLornan, Nicola Polverelli 2024 updates on risk stratification and medical treatment options (15 Min) Francesca Palandri New drugs and integrated approaches: is there a need for novel outcome measures? (15 Min) Giuseppe A. Palumbo Role of transplant in MF in contemporary years: who and when (15 Min) Nico Gagelmann The importance of cooperative studies: the experience of the Chronic Malignancies Working Party of the EBMT (15 Min) Donal McLornan Session 7 - Evolving landscape in Ph- MPNs -16.30 Moderator: Nico Gagelmann, Domenico Russo MPNs: an example of inflammatory disease (15 Min) Alessandro Lucchesi New biological insights into the pathogenesis and progression of MPNs (15 Min) Paola Guglielmelli Current management and unmet needs in ET and PV (15 Min) Barbara Mora End of second day 16.30

